MedTrace Logo

Blood Tuberculosis DNA Levels to Monitor Tuberculosis Treatment

NCT06845618 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 140

Last updated 2026-04-13

No results posted yet for this study

Summary

Tuberculosis (TB) is a leading infectious cause of death worldwide. Current strategies for monitoring TB treatment response are culture dependent and insensitive. New methods of assessing treatment response in vivo could inform new drug development and other treatment strategies. Cell-free DNA (cfDNA) - small circulating fragments of DNA - is widely used in maternofetal medicine and oncology for diagnosis and assessment of treatment response. This study aims to investigate whether pathogen derived Mycobacterium tuberculosis-specific cfDNA (Mtb-cfDNA) can be used to monitor TB treatment response.

This feasibility study will take place at Mae RaMat TB Center in Thailand and includes two study groups:

1. Assay Development and Validation
2. Longitudinal Assessment of Mtb-cfDNA levels

Conditions

  • Mycobacterium Tuberculosis
  • Tuberculosis, Pulmonary
  • Tuberculosis, Extra-Pulmonary

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Timothy Seers, Dr · Mahidol Oxford Tropical Medicine Research Unit, Faculty of Tropical Medicine, Mahidol University.

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-07-21
Primary Completion
2027-09-30
Completion
2027-09-30

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06845618 on ClinicalTrials.gov